Risk of urinary tract infections associated with SGLT2 inhibitor use in patients with RA: a target trial emulation study
Authors' conclusion
Among RA patients with DM, SGLT2i use may inherently increase the risk of UTI compared with other antidiabetics.
Study context
- Population
- RA patients aged ≥18 years with type 2 diabetes mellitus (DM), administrative claim database, April 2015 to April 2023Population 2
- Participants
- 9,772 patients
- Exposure
- SGLT2i vs other antidiabetic drugs
- Outcome
- UTI, defined using diagnostic code and antibiotic prescription
Methodological detailsadministrative claim database, intention-to-treat and as-treated analyses, quasi-Poisson regression (ITT), Poisson mixed-effects models (as-treated (AT))
- Administrative claim database
- Intention-to-treat and as-treated analyses
- quasi-Poisson regression (ITT)
- Poisson mixed-effects models (AT)
Main finding
As reported in the abstract
UTI
- ITT analysis showed no significant difference between SGLT2i and other antidiabetic drug
- Intention-to-treat and as-treated analyses
- 2269 urinary tract infection (UTI) events in 1373 patients during a mean 34-month follow-up
Observational data: associations, not effects.
Further findings
SGLT2i-daily GC dose interaction
- Not significant in either model
Annual trends in diabetes medication (Population 1)
- Population 1 patients
- 26 754
- SGLT2i prescriptions notably increased, while traditional diabetes medications decreased
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Risk of urinary tract infections associated with SGLT2 inhibitor use in patients with RA: a target trial emulation study. Rheumatology (Oxford). Published 4 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →